Back to Landing Page »

OncoSec is a late-stage biotechnology company developing cytokine-based immunotherapies to stimulate the body’s immune response to target and attack cancer using our DNA plasmid-based interleukin-12 (IL-12) gene delivery platform. Through our proprietary technology, we are working to deliver safe and effective cancer treatments that can provide long-term benefits for patients.

OncoSec’s gene delivery technology combines TAVOTM (tavokinogene telseplasmid), DNA plasmid-based IL-12, with an intratumoral gene electrotransfer delivery platform enabling the immune system to target and attack tumors throughout the body. TAVO has demonstrated a local and systemic anti-tumor response in several clinical trials, including the pivotal registration-enabled Phase 2b trial, KEYNOTE-695, for anti PD-1 checkpoint refractory metastatic melanoma and the KEYNOTE-890 Phase 2 trial in metastatic triple negative breast cancer (mTNBC).

Alain Algazi, MD
Associate Professor, Department of Medicine
UCSF Helen Diller Family Comprehensive Cancer Center

Read OncoSec Document »


January 18, 2021

Created by

Scripps CME Connection